External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

WPC 2026

We will be contributing to topics related to
-
09:30 AM
Duration 60mins Phoenix, USA
Prasinezumab in Early-Stage Parkinson's Disease: Additional Data from the PADOVA Study
Tania Nikolcheva
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:30 AM
Duration 60mins Phoenix, USA
A Phase 1b study to test the safety, pharmacokinetics, and pharmacodynamics of selnoflast in early stage Parkinson’s disease
Gennaro Pagano
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Phoenix, USA
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial, 5-year update
Fabiana Gullotta
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Phoenix, USA
Prasinezumab's impact on neuromelanin- and iron-sensitive MRI biomarkers in Parkinson's disease: findings from the PADOVA phase IIB study
Thomas Kustermann
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon